| Not Yet Recruiting | A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Mi NCT07340190 | Novartis Pharmaceuticals | Phase 1 |
| Not Yet Recruiting | Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies NCT07504263 | Recurv Pharma Inc | Phase 1 / Phase 2 |
| Not Yet Recruiting | An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers NCT07426757 | Pfizer | Phase 1 |
| Recruiting | A Study of BR111 in Patients With Advanced Malignancies NCT06937957 | BioRay Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | An Extension Study for Patients Previously Enrolled in Studies With Pelabresib NCT06401356 | Novartis Pharmaceuticals | Phase 3 |
| Recruiting | A Study of IBI363 in Subjects With Advanced Malignancies NCT06468098 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 |
| Not Yet Recruiting | Phase I Study of XZ120 in Malignant Tumors NCT06206915 | Shandong New Time Pharmaceutical Co., LTD | Phase 1 |
| Active Not Recruiting | Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers NCT05891171 | Arcus Biosciences, Inc. | Phase 1 |
| Recruiting | A Study of BRY812 for Injection Alone in Subjects With Advanced Malignancies NCT06038058 | BioRay Pharmaceutical Co., Ltd. | Phase 1 |
| Terminated | Phase I/II Clinical Study of 1A46 Drug Substance NCT05987605 | BioRay Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | A Study of IBI363 in Combination With Bevacizumab or Furuitinib in Subjects With Advanced Colorectal Cancer NCT06717880 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 1 |
| Recruiting | A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Brea NCT06202261 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 / Phase 2 |
| Withdrawn | INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squam NCT05359692 | Incyte Biosciences International Sàrl | Phase 2 |
| Completed | Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies NCT05577182 | Incyte Corporation | Phase 1 |
| Terminated | Clinical Study of BR105 Injection NCT05351697 | BioRay Pharmaceutical Co., Ltd. | Phase 1 |
| Withdrawn | IBI397 or Combination Therapies in Patients With Advanced Malignancies NCT05245916 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 |
| Unknown | Safety, Tolerability, PK, PD, Immunogenicity and Efficacy of TWP-102 in Patients With Advanced Malignancies. NCT05024305 | Shandong TheraWisdom Biopharma Co., Ltd. | Phase 1 |
| Completed | Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antige NCT04837196 | Astellas Pharma Global Development, Inc. | Phase 1 / Phase 2 |
| Terminated | A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients Wit NCT05048134 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Active Not Recruiting | Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are NCT05059522 | Pfizer | Phase 3 |
| Completed | Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies NCT05391022 | Constellation Pharmaceuticals | Phase 1 |
| Terminated | The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies. NCT04949191 | Incyte Corporation | Phase 2 |
| Unknown | Study of IBI323 in Patients With Advanced Malignancies NCT04916119 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 |
| Completed | To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Re NCT04831996 | Incyte Corporation | Phase 1 |
| Unknown | A Clinical Study of MIL93 in Solid Tumors. NCT04671875 | Beijing Mabworks Biotech Co., Ltd. | Phase 1 |
| Completed | To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and NCT04831944 | Incyte Corporation | Phase 1 |
| Recruiting | BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D2 NCT04752826 | BioInvent International AB | Phase 1 / Phase 2 |
| Recruiting | A Clinical Study of MIL95 in Advanced Malignancies. NCT04651348 | Beijing Mabworks Biotech Co., Ltd. | Phase 1 |
| Completed | Safety and Efficacy of IBI322 in Chinese Subjects With Advanced Malignant Tumors NCT04328831 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 |
| Completed | A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-T-cell Immunorecep NCT04353830 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 |
| Completed | Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels NCT04537715 | Epizyme, Inc. | Phase 1 |
| Unknown | A Study of TQB3455 Tablets in Subjects With Advanced Malignancies NCT04340427 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 |
| Active Not Recruiting | Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies NCT04181788 | Pfizer | Phase 1 / Phase 2 |
| Completed | A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors NCT03995472 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Active Not Recruiting | Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies NCT04164199 | BeOne Medicines | Phase 3 |
| Unknown | A Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI110 in Subjects With Advanced Malignan NCT04085185 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 |
| Completed | A Study of SHR-1501 in Patients With Advanced Tumors NCT04025957 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Completed | A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With A NCT03907969 | AstraZeneca | Phase 1 / Phase 2 |
| Completed | A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differenti NCT03763149 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 |
| Completed | A Phase 1 Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI188 in Advanced Malignancies NCT03717103 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 |
| Terminated | Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies NCT03407976 | University of Utah | Phase 1 |
| Completed | Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malign NCT03474640 | TopAlliance Biosciences | Phase 1 |
| Terminated | INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies NCT03277352 | Incyte Biosciences International Sàrl | Phase 1 / Phase 2 |
| Completed | A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or M NCT03241173 | Incyte Biosciences International Sàrl | Phase 1 / Phase 2 |
| Completed | A Study of PLX2853 in Advanced Malignancies. NCT03297424 | Opna Bio LLC | Phase 1 |
| Active Not Recruiting | Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japan NCT03233139 | Regeneron Pharmaceuticals | Phase 1 |
| Completed | A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread NCT03158272 | Bristol-Myers Squibb | Phase 1 |
| Completed | Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies NCT03126110 | Incyte Biosciences International Sàrl | Phase 1 / Phase 2 |
| Terminated | Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206) NCT02959437 | Incyte Corporation | Phase 1 / Phase 2 |
| Completed | A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic NCT02923349 | Incyte Biosciences International Sàrl | Phase 1 / Phase 2 |
| Unknown | PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor NCT02873390 | Ningbo Cancer Hospital | Phase 1 / Phase 2 |
| Unknown | Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Gastric Cancer NCT02862561 | Shanghai International Medical Center | Phase 1 / Phase 2 |
| Completed | A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors NCT02697591 | Incyte Biosciences International Sàrl | Phase 1 / Phase 2 |
| Completed | ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced NCT02737501 | Ariad Pharmaceuticals | Phase 3 |
| Completed | Phase I Study of PDR001 in Patients With Advanced Malignancies. NCT02678260 | Novartis Pharmaceuticals | Phase 1 |
| Terminated | Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Maligna NCT02608268 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Withdrawn | Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study NCT02520245 | Regeneron Pharmaceuticals | Phase 1 |
| Completed | Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies NCT02383212 | Regeneron Pharmaceuticals | Phase 1 |
| Terminated | An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies NCT02265510 | Incyte Corporation | Phase 1 / Phase 2 |
| Completed | A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Sub NCT02013804 | MedImmune LLC | Phase 1 |
| Completed | Safety Study of Two Oral Formulations of MGCD265 Administered in Healthy Subjects in the Fasting State NCT01930006 | Mirati Therapeutics Inc. | Phase 1 |
| Completed | Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lym NCT01284192 | Astellas Pharma Inc | Phase 1 |
| Completed | A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1 NCT00948961 | Celldex Therapeutics | Phase 1 / Phase 2 |
| Completed | Maintenance Study on the Long Term Safety of XL999 NCT00955084 | Symphony Evolution, Inc. | Phase 1 |
| Completed | A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies NCT00741403 | Cornerstone Pharmaceuticals | Phase 1 |
| Terminated | A Phase 1 Dose Escalation Study of IPI-493 NCT00724425 | Infinity Pharmaceuticals, Inc. | Phase 1 |
| Completed | Safety Study of Oral MGCD265 Administered With Interruption to Subjects With Advanced Malignancies NCT00679133 | Mirati Therapeutics Inc. | Phase 1 |
| Unknown | Everolimus and Capecitabine in Patients With Advanced Malignancy NCT01079702 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Phase 1 / Phase 2 |
| Completed | A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Participants Wi NCT00651664 | Millennium Pharmaceuticals, Inc. | Phase 1 |
| Completed | A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors NCT00500903 | Millennium Pharmaceuticals, Inc. | Phase 1 |
| Terminated | The Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced M NCT00468260 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Evaluate the Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With A NCT00448396 | Novartis Pharmaceuticals | Phase 1 |
| Completed | A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced NCT00676299 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 1 |
| Completed | Pharmacokinetics of Patupilone After a Single Intravenous Administration in Patients With Advance Solid Tumor NCT00426140 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Clinical Trial of Continuing Treatment for Patients Who Have Participated on a Prior Protocol Investigating Ta NCT00779428 | Bristol-Myers Squibb | Phase 2 |
| Completed | A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function NCT00421044 | Novartis Pharmaceuticals | Phase 1 |
| Terminated | A Phase 1 Trial of Extended MLN8054 Dosing in Patients With Advanced Malignancies NCT00652158 | Millennium Pharmaceuticals, Inc. | Phase 1 |
| Completed | A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function NCT00420524 | Novartis Pharmaceuticals | Phase 1 |
| Completed | PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies NCT00611793 | SCRI Development Innovations, LLC | Phase 1 |
| Completed | Urokinase-Plasminogen Activator (uPA) Inhibitor WX-UK1 in Combination With Capecitabine in Advanced Malignanci NCT00083525 | Heidelberg Pharma AG | Phase 1 |
| No Longer Available | An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer NCT02784158 | Ariad Pharmaceuticals | — |